Gastric leiomyosarcoma

Summary

Gastric leiomyosarcoma (MONDO:0003367) is a disease. A subtype of gastric cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric leiomyosarcoma
Mondo ID	MONDO:0003367
DOID	DOID:5280
ICD-11	399434138
NCIT	C27200
SNOMED CT	447785000
UMLS	C0744295
MedGen	196652
GARD	0023480
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	no

Also known as: gastric leiomyosarcoma · gastric leiomyosarcoma (disease) · leiomyosarcoma of stomach · stomach leiomyosarcoma

Data availability: 1 HPO phenotype · 1 cell line.

Disease family

This is a subtype of gastric cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastric cancer › gastric leiomyosarcoma

Related subtypes (8): malignant gastric granular cell tumor, gastric lymphoma, pylorus cancer, cardia cancer, malignant gastric germ cell tumor, gastric liposarcoma, gastric carcinoma, diffuse gastric cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.